We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

146 hedge funds and large institutions have $460M invested in iTeos Therapeutics in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more call options, than puts

Call options by funds: $1.38M | Put options by funds: $1.01M

21% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 47

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3.51% less ownership

Funds ownership: 100.73% → 97.22% (-3.5%)

5% less funds holding

Funds holding: 153 → 146 (-7)

6% less capital invested

Capital invested by funds: $489M → $460M (-$28.4M)

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

Holders
146
Holders Change
-7
Holders Change %
-4.58%
% of All Funds
2.29%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
57
Reduced
47
Closed
25
Calls
$1.38M
Puts
$1.01M
Net Calls
+$367K
Net Calls Change
+$993K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$4.25M
2
BlackRock
BlackRock
New York
+$3.09M
3
Goldman Sachs
Goldman Sachs
New York
+$2.93M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$2.44M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.32M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$7.21M
2
Morgan Stanley
Morgan Stanley
New York
-$5.51M
3
Invesco
Invesco
Georgia
-$5.32M
4
State Street
State Street
Massachusetts
-$3.74M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$3.1M +$2.44M +171,389 New
Invesco
27
Invesco
Georgia
$2.85M -$5.32M -373,194 -63%
Charles Schwab
28
Charles Schwab
California
$2.53M +$113K +7,947 +4%
Morgan Stanley
29
Morgan Stanley
New York
$2.34M -$5.51M -386,534 -69%
BCM
30
Bridgeway Capital Management
Texas
$2.22M -$1.41M -99,141 -37%
BBA
31
Baker Bros. Advisors
New York
$1.99M – – –
Principal Financial Group
32
Principal Financial Group
Iowa
$1.94M -$119K -8,370 -5%
SAM
33
Sectoral Asset Management
Quebec, Canada
$1.94M +$830K +58,203 +66%
Vontobel Holding
34
Vontobel Holding
Switzerland
$1.94M +$830K +58,203 +66%
Fidelity Investments
35
Fidelity Investments
Massachusetts
$1.86M -$1.03M -71,998 -34%
Ameriprise
36
Ameriprise
Minnesota
$1.77M -$74.2K -5,206 -4%
PAM
37
Panagora Asset Management
Massachusetts
$1.6M +$61.4K +4,305 +4%
Verition Fund Management
38
Verition Fund Management
Connecticut
$1.54M +$1.66M +116,283 New
Bank of America
39
Bank of America
North Carolina
$1.53M -$596K -41,766 -26%
Los Angeles Capital Management
40
Los Angeles Capital Management
California
$1.46M +$39.9K +2,800 +3%
EST
41
EA Series Trust
Pennsylvania
$1.34M +$1.44M +101,304 New
EF
42
Empowered Funds
Pennsylvania
$1.34M +$1.44M +101,304 New
Victory Capital Management
43
Victory Capital Management
Texas
$1.31M +$204K +14,333 +17%
DCM
44
DAFNA Capital Management
California
$1.3M – – –
RAM
45
Readystate Asset Management
Illinois
$1.17M +$1.26M +88,391 New
Rafferty Asset Management
46
Rafferty Asset Management
New York
$1.15M -$391K -27,452 -24%
Massachusetts Financial Services
47
Massachusetts Financial Services
Massachusetts
$1.08M -$27.3K -1,913 -2%
D.E. Shaw & Co
48
D.E. Shaw & Co
New York
$1.05M +$97.2K +6,816 +9%
N
49
Nuveen
North Carolina
$1M -$308K -21,571 -22%
BFM
50
Boothbay Fund Management
New York
$1,000K +$568K +39,848 +112%
1
2
3 4 5

ITOS Hedge Fund Activity: Q2 2023 in Review

146 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q2 2023, worth a combined $460M — down 5.8% from $489M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of ITOS and 18 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 57 added.

The largest buyer was Millennium Management, adding an estimated $4.25M. The largest seller was JP Morgan Chase, cutting an estimated $7.21M.

  • 146 institutional investors held iTeos Therapeutics (ITOS) as of Q2 2023, down from 153 in Q1 2023.
  • Funds reported $460M of iTeos Therapeutics stock for Q2 2023, down 5.8% quarter-over-quarter.
  • 18 funds opened new iTeos Therapeutics positions in Q2 2023 and 25 closed out, a net change of -7 holders.
  • The largest iTeos Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $4.25M added.
  • The largest iTeos Therapeutics seller in Q2 2023 was JP Morgan Chase, an estimated $7.21M sold.

Based on aggregated 13F filings for Q2 2023.